Atlas Trials

Surufatinib Combined With Serplulimab Plus Chemotherapy in the Treatment of Extensive-stage Small Cell Lung Cancer

Clinical trial NCT05882630 · UNKNOWN

Trial details

NCT number
NCT05882630
Sponsor
Fujian Cancer Hospital
Status
UNKNOWN
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Small Cell Lung Cancer
Start date
2023-06-01
Primary completion
2025-06-01
Enrollment
39

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.